Evaluation of Patient Characteristics and Treatment Approaches to Patients With Bipolar Disorder in Turkey
Completed
- Conditions
- Bipolar Disorder
- Registration Number
- NCT00660712
- Lead Sponsor
- AstraZeneca
- Brief Summary
A registry study to identify the patient-diagnosis-treatment characteristic profile of patients with bipolar disorder in Turkey.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1018
Inclusion Criteria
- Patients previously or currently diagnosed with bipolar disorder
- Patients (or any of their relatives) who give a written informed consent.
Exclusion Criteria
- Patients who were previously included in this study.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Identification of the patient-diagnosis-treatment characteristic profile of patients with bipolar disorder in Turkey.
- Secondary Outcome Measures
Name Time Method Identification of treatment modalities selected according to the disease phase Identification of the number of first degree relatives diagnosed with bipolar disorder Evaluation of the relationship between patient and disease characteristics Evaluation of co-morbid psychiatric diseases Evaluation of the time period that elapsed since the diagnosis of bipolar disorder
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What patient characteristics are associated with treatment outcomes in NCT00660712 bipolar disorder registry?
How do molecular mechanisms of mood stabilizers influence treatment approaches in Turkish bipolar populations?
What biomarkers predict response to standard-of-care treatments in bipolar disorder as identified in Turkey registries?
What adverse events are commonly reported in bipolar disorder treatment strategies in Turkey?
How do AstraZeneca's observational studies on bipolar disorder compare to global treatment guidelines and registries?
Trial Locations
- Locations (1)
Research Site
🇹🇷Trabzon, Turkey
Research Site🇹🇷Trabzon, Turkey